Agreed, and what I was alluding to is that others trying to do their own keytruda would face a moat around a lot of the treatable cases because presumably they would want the combo, giving Merck/nwbo the business. Who wouldn’t want the best shot at survival.
News 
Market Data 
Discover 
AI
